

CSD/BSE&NSE/2022-2023  
October 4, 2022

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**  
**Scrip Code: 543064**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**  
**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: News Release**

.....

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), please find enclosed News Release of our company titled **“Casper Pharma Receives EIR from USFDA for its PAI (pre-approval inspection)”**.

This is for your information and record.

Thanking you,  
Yours faithfully,  
**For Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

Encl: as above

**Suven Pharmaceuticals Limited**

## News Release

### Casper Pharma Receives EIR from USFDA for its PAI (pre-approval inspection)

HYDERABAD, INDIA (October 4, 2022) – Suven Pharmaceuticals Ltd announces today that the US Food and Drug Administration (USFDA) has issued an EIR for its wholly owned Subsidiary Casper Parma Private Limited, a finished dosage drug Manufacturer for human use.

The pre- approval inspection was conducted during 25th July 22 through 29th July 22

Pre-Approval Inspections covering of three applications: NDA 016084, ANDA 217020, & ANDA 217030.

The inspection concluded with no observation (FDA-483) issued.

EIR received from US FDA states that the site is recommended for approval of the three NDA & ANDA listed above.

We are glad to have completed the first ever US FDA audit of this facility successfully with Zero observations and now with the receipt of EIR recommending the site says Venkat Jasti, Managing Director of Suven Pharmaceuticals Limited.

**Risk Statement:**

*Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.*

## Suven Pharmaceuticals Limited